Cipla FY26 Annual Earnings Summary
4 quarters covered · ₹28,161 Cr revenue · ₹3,868 Cr PAT · 20.8% average EBITDA margin.
Quarter-by-quarter progression
Management promises made during the year
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q1 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q2 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q2 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q3 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q4 FY26Risks flagged during the year
Management could not provide precise timing of Revlimid revenue decline, which may impact quarterly US revenue and margins.
Q1 FY26 · highIndore facility is due for US FDA reinspection within the next year; any adverse outcome could disrupt US supplies.
Q2 FY26 · highGeneric Revlimid contribution expected to become immaterial from Q3 FY26, creating a revenue gap that new launches may not fully offset in the near term.
Q3 FY26 · highPharmathen's manufacturing pause and 483 observations could delay resupply, impacting U.S. revenue.
Q3 FY26 · highRespiratory and peptide launches are critical to offset Lenalidomide decline; any delay or increased competition could pressure revenue.
Q4 FY26 · highLanreotide remains off market due to partner remediation; timeline for return is uncertain, with alternate supplier filing expected by Q4 FY27.
Q1 FY26 · mediumIndia branded business grew only ~3% (ex-consumer), impacted by slow respiratory/acute market and sales force realignment; recovery may take longer.
Q1 FY26 · mediumManagement acknowledged GLP-1 market will be crowded; Cipla's strategy is still evolving and may face challenges in capturing share.
Q2 FY26 · mediumDelays in FDA approvals for key respiratory and peptide assets could impact the $1B US revenue target.
Q2 FY26 · mediumIndia branded business grew only 7% YoY, below the market, due to weak acute season and team restructuring.
Q2 FY26 · mediumPotential competition from semaglutide generics and uncertainty over exclusivity terms with Lilly could limit tirzepatide upside.
Q3 FY26 · mediumR&D at 7% of revenue is above historical 5-6% range; management expects normalization but lumpy spending could continue.
What changed through the year
Q1 FY26 · FY26 EBITDA margin guidance maintained at 23.5%-24.5%
Management reiterated the full-year EBITDA margin range despite Q1 margin of 25.6% being above the range, citing potential Revlimid phasing and R&D investments.
Q1 FY26 · US revenue target of ~$1 billion by FY27
CEO stated pipeline (including respiratory launches like generic Symbicort) should get US revenue closer to or surpass $1 billion by FY27.
Q1 FY26 · India branded business to grow in line with IPM in next three quarters
COO expressed confidence that India branded prescription business will grow at industry rates for the remaining quarters of FY26.
Q1 FY26 · Biosimilar launch in US expected in Q2 FY26
Company signed agreement to launch first biosimilar in US (supportive care in oncology) via partnership; own biosimilars expected by 2029-30.
Q2 FY26 · FY26 EBITDA margin guidance revised to 22.75%-24%
Full-year EBITDA margin guidance lowered from 23.5%-24.5% due to higher R&D spend and declining Revlimid contribution.
Q2 FY26 · Generic Revlimid contribution immaterial from Q3 FY26
Revlimid revenue expected to be very small in Q3 and decline further as patent expires in January.
Q2 FY26 · Launch of four major respiratory assets by CY26
Includes generic Advair in Q4 2026 and three peptide assets including liraglutide.
Q2 FY26 · US revenue directional target of $1B next year
Run-rate expected to reach $1B in US revenue during next fiscal year, subject to approval timelines.
Q3 FY26 · FY26 EBITDA margin guidance revised to ~21%
Management lowered FY26 EBITDA margin guidance to ~21% from earlier expectations, citing lower lanreotide and Lenalidomide impact.
Q3 FY26 · U.S. launches: 4 respiratory and 4 peptide assets in FY27
Pipeline includes generic Advair, two other large respiratory assets (likely Symbicort), and three peptide launches including generic Victoza.
Q3 FY26 · Lanreotide resupply expected in H1 FY27
Partner Pharmathen paused production; resupply expected in H1 FY27, with alternate site evaluation underway.
Q3 FY26 · FY27 guidance to be provided next quarter
Management will provide FY27 guidance after finalizing the annual operating plan.
Q4 FY26 · FY27 EBITDA margin guidance of 18.5-20%
Management expects EBITDA margins in the range of 18.5-20% for FY27, with sequential improvement and stronger H2.
Q4 FY26 · US business to reach $1B run-rate by FY27-end
Cipla targets a $1 billion annualized run-rate for US business by end of FY27, driven by respiratory and peptide launches.
Q4 FY26 · India business to deliver double-digit growth in FY27-28
Management expects strong double-digit and market-beating growth in India for FY27 and FY28.
Q4 FY26 · R&D spend to remain around 7% of sales
R&D investment will continue at approximately 7% of revenue, supporting complex generics and biosimilars pipeline.